Qihan Biotech
Latest round
- Series A
Last raised
- Mar 2021
Total raised
- $100M
Investors
- 10
About Qihan Biotech
Established in 2017 and based in Hangzhou, China, Qihan Biotech is a biotechnology company that provides novel immune-privileged cell and organ therapies. The company's chairman, Steven Holtzman is a former CEO of Decibel Therapeutics, former EVP corporate development of Biogen, and founder of DNX. The company's founder & CEO, Luhan Yang holds a PhD in Human Biology and Translational Medicine from Harvard Medical School. She is the co-founder, former president & CSO of eGenesis, and co-inventor of CRISPR-Cas9 technologies. The company builds an immune-privileged cell and organ platform to produce cells and organs that can evade immune attacks, such as natural killer cells for immune oncology, cardiomyocytes, neurons, and islet cells for regenerative medicine. It also produces animals with enhanced agronomical traits or multi-disease resistance in agriculture through multi-genome editing technology. The company will use the funds to support product iteration and global development of gene-edited stem cell products.
Who invested in Qihan Biotech
10 investors across 3 rounds
See all investors in Qihan Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Qihan Biotech
Who invested in Qihan Biotech?
Qihan Biotech has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Qihan Biotech raised?
Qihan Biotech has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Qihan Biotech last raise money?
Qihan Biotech's most recent round on record is a Series A, in Mar 2021.
What does Qihan Biotech do?
Established in 2017 and based in Hangzhou, China, Qihan Biotech is a biotechnology company that provides novel immune-privileged cell and organ therapies.
Where is Qihan Biotech headquartered?
Qihan Biotech is headquartered in Hangzhou, China.
Which VCs invest in companies like Qihan Biotech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Qihan Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Qihan Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.